EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy and safety of therapeutic procedure for Waldenström's macroglobulinemia with hyperviscosity syndrome

Kenichi Ito iD, Tomoki Kawasaki, Kazuhiko Hirano, Naohiro Sekiguchi iD

Therapeutic Apheresis and Dialysis · 2024

DOI: 10.1111/1744-9987.14094 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Apheresis and Dialysis, 2024. Verfasst von Kenichi Ito und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan. Hauptthemen laut MEDLINE: Waldenstrom Macroglobulinemia, Plasmapheresis, Blood Viscosity, Immunoglobulin M. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hyperviscosity syndrome (HVS) is a significant complication in Waldenström's macroglobulinemia (WM), although the significance of plasmapheresis in clinical practice has not been clarified. To confirm the efficacy and safety of plasmapheresis followed by primary therapy for WM with HVS, we retrospectively conducted this study.

Methods

Untreated WM with HVS, or serum immunoglobulin M (IgM) levels ≥4000 mg/dL, were analyzed. The basic therapeutic flow was conducted as follows: (1) performing plasmapheresis, (2) followed by primary therapy without rituximab, and (3) performing the second cycle. The serum IgM reduction rate and adverse events (AEs) were evaluated.

Results

Ten patients were enrolled. The median serum IgM levels at diagnosis, post‐plasmapheresis, after the first cycle of primary therapy, and after the second cycle were 5174, 2900, 3286, and 2657 mg/dL, respectively. No patients experienced IgM flare or bleeding AEs.

Conclusion

The therapeutic flow offers sufficient efficacy and safety in WM with HVS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Waldenstrom MacroglobulinemiaPlasmapheresisBlood ViscosityImmunoglobulin MHumansMaleFemaleRetrospective StudiesAgedMiddle AgedTreatment OutcomeSyndromeRituximabAged, 80 and over

Stichwörter der Autor:innen

Waldenström's macroglobulinemiaacquired von Willebrand diseasehyperviscosity syndromeplasma exchange

Substanzen

Immunoglobulin MRituximab

Autor:innen und Institutionen

  • Hematology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
  • Nephrology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
  • Laboratory and Pathology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
  • Clinical Research Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan.

ORCID-Profile: Kenichi Ito, Naohiro Sekiguchi

Zitieren

APA

Ito, K., Kawasaki, T., Hirano, K., & Sekiguchi, N. (2024). Efficacy and safety of therapeutic procedure for Waldenström's macroglobulinemia with hyperviscosity syndrome. Therapeutic Apheresis and Dialysis. https://doi.org/10.1111/1744-9987.14094

Vancouver

Ito K, Kawasaki T, Hirano K, Sekiguchi N. Efficacy and safety of therapeutic procedure for Waldenström's macroglobulinemia with hyperviscosity syndrome. Therapeutic Apheresis and Dialysis. 2024. doi:10.1111/1744-9987.14094

BibTeX
@article{Ito2024,
  author = {Ito, Kenichi and Kawasaki, Tomoki and Hirano, Kazuhiko and Sekiguchi, Naohiro},
  title = {Efficacy and safety of therapeutic procedure for Waldenström's macroglobulinemia with hyperviscosity syndrome},
  journal = {Therapeutic Apheresis and Dialysis},
  year = {2024},
  doi = {10.1111/1744-9987.14094}
}
Kostenlos starten →